




Alcidion Group Limited

AGM Presentation

November 2016



Disclaimer

This presentation has been prepared by Alcidion Group Limited (the "Company"). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).


Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other Jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.



ASX Ticker

ALC

Market Capitalisation

\$69.23 million

Ownership

40% Founders
15% BlueSky Private Equity
11% Owned by Employees

Share Price

11.50c

Cash on hand

\$6+ million

Enterprise Value

\$63 million

Shares on Issue

603 million

Employees

30 x FTE

Revenues FY16

\$4 million

Cumulative R&D Investment

~\$19 million

Performance Shares

*\$4m in script on achieving \$10m in TTM revenue by 29/2/2018 and;
\$4m in script on achieving \$15m in TTM revenue within 29/2/2019 .*


*All financial data has been rounded as of 3 October 2016
Equity data accurate as of 21 November 2016*




INVESTOR RELATIONS

TOP SHAREHOLDERS CONSOLIDATED BY COMMON ADDRESS

No	Shareholder	Shares	Percentage
1	Dr Malcolm Pradhan	139,861,782	23.20%
2	Mr Raymond Blight & Ms Robyn Morris	100,770,933	16.72%
3	BSPE Medical Technology Pty Ltd	90,863,812	15.07%
4	Allure Capital Pty Ltd	16,717,243	2.77%
5	Dr Victor Wilk	9,650,000	1.60%
6	Citicorp Nominees Pty Limited	6,391,173	1.06%
7	Mr Pierre Pulko	4,000,000	0.66%
8	Mr Duncan Craig	3,873,101	0.64%
9	Ms Lin Lin	3,870,437	0.64%
10	Mr Phillip Coulson	3,177,329	0.53%
11	Walani Pty Ltd	3,177,329	0.53%
12	Pershing Australia Nominees Pt Y Ltd	3,067,850	0.51%
13	Walsh Prestige Pty Ltd	3,000,001	0.50%
14	Mr Peter Checkley + Ms Niomie Varady	2,934,552	0.49%
15	Comsec Nominees Pty Limited	2,892,352	0.48%
16	Mr Mike Massen	2,842,090	0.47%
17	Mr Jacob Coulson	2,541,863	0.42%
18	Allekian Exchange Pty Ltd	2,500,000	0.41%
19	Mr Vince Truda	2,500,000	0.41%
20	Mr John Lovell & Mrs Jodi Lovell	2,450,000	0.41%
21	Mr Dennis O'Farrell + Mrs Oksana O'Farrell	2,332,041	0.39%
22	Yavern Creek Holdings Pty Ltd	2,300,000	0.38%
23	Mrs Sofiah Valibhoy	2,271,000	0.38%
24	Jayarajan Investments Pty Ltd	2,243,544	0.37%
25	STO Capital Pty Ltd & Drapua Capital Pty Ltd	2,170,000	0.36%
26	Myjd Pty Ltd	2,064,018	0.34%
27	Mr Brian Leedman & Mrs Natasha Leedman	2,000,000	0.33%





ID	Name	31/07/2015	27/11/2016
1	KONKERA PTY LTD <KONKERA FAMILY A/C>	7,800,000	-
2	BLU BONE PTY LTD	6,700,000	-
3	KOBIA HOLDINGS PTY LTD	6,700,000	-
4	UPSKY EQUITY PTY LTD <UPSKY INVESTMENT A/C>	6,700,000	-
5	MR JOHN HENRY TOLL <TOLL FAMILY DISCRET A/C>	4,030,000	-
6	SABRELINE PTY LTD <JPR INVESTMENT A/C>	4,000,000	-
7	WILDGLADE PTY LTD <THE RALSTON FAMILY A/C>	3,225,000	-
8	POLARITY B PTY LTD	3,000,000	-
9	MR TERRENCE PETER WILLIAMSON + MS JONINE MAREE JANCEY	2,560,004	-
10	MGL CORP PTY LTD	486,782	-
11	TCH HOLDINGS PTY LTD <THE TRAVIS INVESTMENT A/C>	2,000,000	-
12	VFT INVESTMENTS PTY LTD	1,500,000	-
13	MS LORAIN VON DER WEID-DE WECK	1,825,000	-
14	MR VINCE TRUDA <VINCE TRUDA S/F A/C>	1,750,000	1,750,000
15	SMAC NOMINEES PTY LTD <SMAC INVESTMENT A/C> ** ESCROWED **	1,600,000	1,270,931
16	NEFCO NOMINEES PTY LTD	1,577,490	-
17	TT NICHOLLS PTY LTD <SUPERANNUATION FUND A/C>	1,485,931	-
18	MR STEVEN DAVID CRABBE	2,000,000	-
19	MR MARK JOHN BAHEN + MRS MARGARET PATRICIA BAHEN	1,357,308	-
20	MR STEPHEN WOODS	1,556,939	332,389
	TOTAL	61,854,454	3,353,320



WHY IS DIGITAL HEALTH SUCH AN EXCITING INVESTMENT OPPORTUNITY ?

- The global population is aging, resulting in a dramatic and unparalleled increase in population, complex patients with multiple co-morbidities.
- The United States spends 18% of GDP on Healthcare, representing over \$USD3 trillion dollars annually, which is set to grow to 37% by 2050.
- Global expenditure on Healthcare IT is \$USD40 billion, growing to \$USD57 billion by 2017.





WHY IS DIGITAL HEALTH SUCH AN EXCITING INVESTMENT OPPORTUNITY ?

- The Patient Protection & Affordable Care in 2010, mandated that all US hospitals upgrade their Clinical Information Systems.
- This HITECH Act stipulates that healthcare providers must demonstrate the meaningful use of health IT by 2016 or face a reduction in Medicare reimbursements.
- Global Healthcare organisations are embracing EMRAM to improve efficiency in Healthcare.




- FDA Regulating the environment.
- The Global Governments are allocating funds to Digital Health:
 - The United States government has set aside more than \$USD20 billion in stimulus funds to implement Electronic Health Records nationwide
 - The United Kingdom has allocated £4 billion to transition the National Health Service into a paperless environment.
 - Australian Digital Health Agency formed 27th Jan 2016.
- The adoption of Digital Health encourage the adoption of Digital Health – a self fulfilling prophecy.





“This has skyrocketed the efficiency in patient care as well as the **safety**”

Professor Tissa Wijerante
Consulting Neurologist
Director of the Stroke & Neuroscience Unit
Western Health



“You’ll see nearly all of the clinical, executive and divisional directors walking around with the bed management views on their iPads, and the same with the bed management staff, the quality managers, the NUMs and any staff that help move the patients around.”

Jason Whakaari
Executive Director of ICT, Western Health



**Chief Medical Officer
Prof. Malcolm Pradhan**

- Formal qualifications in medicine complimented by a PhD in Medical Informatics from Stanford University.
- Founding fellow of the Australasian College of Health Informatics.
- Associate Dean of IT & Director of Medical Informatics at the University of Adelaide.
- Clinical Lead within the Australian Government's National e-Health Transition Authority.



**Chief Executive Officer
Mr. Ray Blight**

- Formal qualifications include a Bachelor of Technology, Bachelor of Economics and a MBA.
- Former CEO of the South Australian Health Commission and Chair of the Health Ministers' Advisory Council
- Consultant to the World Bank.
- Chairs the University of SA IT & Mathematical Sciences Advisory Board.



**Executive Director
Mr. Nathan Buzza**

- Former founder & CEO of Clinical Middleware provider, Commtech Wireless.
- EY "Entrepreneur of the Year".
- BRW in the Fast100 for three consecutive years.
- Western Australia IT & telecommunications Life Time achievement Award for contribution to the IT community.
- Previously the second largest shareholder of Azure Healthcare ([ASX:AZV](#)).



**Non-Executive Director
Mr. Brian Leedman**

- Formal qualifications include a Bachelor of Economics and a MBA.
- Co-Founder of Resapp Health ([ASX:RAP](#)).
- Co-Founder of Oncosil Medical ([ASX:OSL](#)).
- Co-Founder of Imugene ([ASX:IMU](#)).
- WA Chairman of AusBiotech.
- Previously Marketing Manager at Ernst & Young.



**Non-Executive Director
Mr. Nick Dignam**

- Formal qualifications include a Bachelor of Commerce, Bachelor of Law and a Masters of Applied Finance.
- Investment Director of BlueSky ([ASX:BLA](#)), a listed alternative asset manager with \$1.7b of assets under management.
- Responsible for originating new investment opportunities, working with portfolio companies to deliver growth and managing exit processes.
- Joined Blue Sky from Catalyst Investment.



**Non-Executive Director
Mr. Josh Puckridge**

- Formal qualifications include a Bachelor of Commerce.
- Director of Cicero Advisory Services.
- Executive Director of Red Gum Resources.
- Formerly Executive Director and Chief Executive of Discovery Resources Limited.
- Founding Director of Windward Resources Limited([ASX:WIN](#)).
- Non-Executive Director of Top Tung Limited.

- Hospitals are built upon a complex eco-system of disparate Clinical Information Systems.
- Alcidion's Miya platform integrates disparate Clinical Information Systems to identify emerging clinical risk and push this clinical intelligence to the care team via a continuum of mobile and desktop devices.
- Under the stewardship of our CMO, Professor Malcolm Pradhan and CEO Ray Blight, the former Chief Executive of the SA Health Commission, Alcidion has invested over \$18m in the development of the Miya Platform.



- The technology is already deployed and operational at:
 - Western Health.
 - Northern Territory Health Department.
 - Tasmania Health.
 - Royal Melbourne Hospital.
- By providing clinicians with decision support tools and prompting care guidance in accordance with hospital approved clinical protocols, patient clinical outcomes may be improved.

Alcidion is intending to revolutionize the healthcare industry, by providing an agnostic Clinical Information System that resides over the top of the existing systems.





Unique Opportunity To Be Part of the New Digital Health Economy

AFFORDABLE CARE ACT

The introduction of the Patient Protection & Affordable Care Act requires US hospitals to adopt Electronic Medical Records or face a reduction in Medicare reimbursements.

Experienced Management Team



“Capable and Experienced Management Team with a strong track record of commercializing healthcare software, including the former CEO & Chairman of the South Australian Health Commission, a Stanford qualified Medical Doctor and a former Ernst & Young Entrepreneur of the Year.”

Proven Technology

Alcidion's platform is installed into 11 large tertiary hospitals including Footscray, Sunshine, Williamstown, Royal Darwin & Alice Springs Hospitals and throughout Tasmania.

Disruptive Technology Platform

A person wearing a white hospital gown and a wristband is lying in a hospital bed. They are holding a tablet computer with both hands. The tablet screen displays a medical dashboard with various charts, graphs, and data points. The background is slightly blurred, showing the hospital bed and some papers.

The platform is at the forefront of medical technology, on the crest of the next generation of healthcare technologies.



Strong Growth Platform

The business recently secured a \$2.35m MoU with Western Health to adopt its Patient Flow Solutions across its three locations.

The business recently secured a \$2.35m MoU with Western Health to adopt its Patient Flow Solutions across its three locations.



Fully Funded

The recent listing of Alcidion on the ASX will see the company fully funded, with \$6m in cash and debt free.



QUESTIONS ?